AirNexis Therapeutics

AirNexis Therapeutics Launches with $200M Series A

AirNexis Therapeutics has emerged from stealth with $200 million in Series A financing to advance a novel therapy for chronic obstructive pulmonary disease (COPD).

The round was led by Frazier Life Sciences with participation from OrbiMed, SR One, Goldman Sachs, Longitude Capital, and Enavate Sciences.

Key Highlights

• One of the largest Series A rounds in biotech
• Novel dual PDE3/4 inhibitor for COPD
• Combines bronchodilation and inflammation reduction

Company Overview

AirNexis Therapeutics is developing a dual PDE3/4 inhibitor that combines bronchodilation with anti-inflammatory effects, potentially offering COPD patients a more effective treatment option.